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oRIGINAL ARTICLE
Introduction: Traditional tumor-based staging systems provide lim-
ited information on the best treatment option for individual patients 
with advanced inoperable non-small cell lung cancer (NSCLC). The 
Glasgow prognostic score (GPS) reflects the host systemic inflam-
matory response and is a validated independent prognostic factor 
in these patients. The aim of this study was to examine the clinical 
application of the pretreatment GPS in a mature cohort of patients 
with inoperable NSCLC.
Methods: The data of 261 patients with inoperable NSCLC were 
collected prospectively and before treatment. Information on patient 
demographics, body mass index, performance status (PS), the modi-
fied Glasgow prognostic score (mGPS), the prognostic index, and 
treatment received were included.
Results: The majority of patients were aged 65 years or older (68%), 
were men (59%), had a body mass index more than 20 (89%), and an 
Eastern Cooperative oncology Group performance status (ECoG-PS) 
0 or 1 (54%). Most patients had a pretreatment mGPS = 1 (62%) and 
pretreatment prognostic index = 1 (56%). During the follow-up period, 
248 (95%) patients died, 246 from their disease. The median survival 
was 8 months. on multivariate analysis, age (p = 0.001), ECoG-PS 
(p < 0.05), mGPS (p < 0.0001), and tumor stage (p < 0.0001) were 
independently associated with cancer-specific survival. Using 5-year 
cancer-specific mortality as an end point, the area under the receiver 
operator curve was 0.735 (95% confidence interval [CI], 0.566–0.903; 
p = 0.024) for the mGPS, 0.669 (95% CI, 0.489–0.848; p = 0.106) for 
ECoG-PS, and 0.622 (95% CI, 0.437–0.807; p = 0.240) for tumor, 
node, metastasis stage. Patients with an increased mGPS were more 
likely to have a poorer ECoG-PS (p < 0.05), an increased white cell 
count (p < 0.05), and received palliative treatment (p < 0.05).
Conclusion: The pretreatment mGPS is a useful and important pre-
dictor of cancer-specific survival in patients with inoperable NSCLC. 
Basing clinical assessment on the mGPS has implications for the rou-
tine monitoring and treatment of the patients.
Key Words: Non-small cell lung cancer, Clinical utility, Glasgow 
prognostic score.
(J Thorac Oncol. 2012;7:655–662)
Non-small cell lung cancer (NSCLC) remains the common-est cause of cancer deaths in Western Europe and North 
America. Approximately 39,000 new cases are diagnosed 
each year in the United Kingdom.1 Most patients present with 
advanced inoperable disease, and the prognosis despite radio-
therapy and chemotherapy in this group of patients is poor. A 
Scottish analysis reported that half of such patients with lung 
cancer die within 4 months of diagnosis.2
Traditional staging and grading systems provide lim-
ited information on determining the best treatment option for 
individual patients with advanced inoperable NSCLC. More 
recently, host factors, including nutritional status, comorbid-
ity, performance status (PS), and the systemic inflammatory 
response, have been recognized to provide information on out-
come in patients with advanced inoperable NSCLC.3–7
There is now good evidence that C-reactive protein 
(CRP),8–10 albumin,11 and their combination,12–14 known as 
the Glasgow prognostic score (GPS), are validated and tumor 
stage-independent prognostic factors in patients with inoper-
able NSCLC.
Therefore, the aim of this study was to examine the clin-
ical application of the pretreatment modified GPS (mGPS) in 
a large mature cohort of patients with inoperable NSCLC.
METHODS
Patients and Staging
Patients presenting with inoperable NSCLC to a multi-
disciplinary clinic at Wishaw General Hospital, Lanarkshire, 
United Kingdom, between May 2001 and November 2004 
were studied prospectively. All patients had cytologically or 
histologically confirmed disease and were staged on the basis 
of clinical findings, chest radiographs and, where appropri-
ate, bronchoscopy, liver ultrasound, isotope bone scan, and 
computerized tomography of the thorax, according to the 
American Thoracic Society tumor, node, metastasis (TNM) 
classifications.15
Patients with conditions known to evoke a  systemic 
inflammatory response, either acute or chronic, were excluded. 
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These were namely (i) previous chemoradiotherapy for other 
clinical indications before this study, (ii) clinical evidence of 
active pretreatment infection, or (iii) chronic active inflam-
matory diseases such as rheumatoid arthritis. The study 
was approved by the Research Ethics Committee at Wishaw 
General Hospital, Lanarkshire, United Kingdom.
Body Mass Index and PS
Body mass index (BMI) and PS (Eastern Cooperative 
oncology Group [ECoG-PS]) were recorded at the time of 
diagnosis. PS was assessed by one of the two consultant respi-
ratory physicians.
mGPS and Prognostic Index
A venous blood sample was obtained, at diagnosis, for 
measurement of white cell count, albumin, and CRP concen-
trations. The coefficient of variation for these methods, over 
the range of measurement, was less than 5% as established by 
routine quality control procedures. The GPS was constructed 
as previously described.16,17 In brief, CRP more than 10 mg/L 
and albumin less than 35 g/dl were each given a score of 1. 
The GPS was calculated as 0, 1, or 2. Importantly, hypoalbu-
minaemia alone in the absence of an increased CRP level did 
not confer a poorer cancer-specific survival in all patients with 
cancer.7,17 As a result, the GPS was modified, and patients with 
hypoalbuminaemia alone were assigned a score of 0.18
The prognostic index (PI) was constructed as previously 
described.19 In brief, CRP more than 10 mg/L and white blood 
cells more than 11  109/L are each given a score of 1. The PI 
is calculated as 0, 1, or 2.
Treatment Received
Patients were considered to have had palliative treatment or 
active treatment as previously described.16 After diagnosis, treat-
ment recommendations for each case were made after discus-
sion at a multidisciplinary meeting according to various factors, 
including disease status, PS, comorbidities, and patient wishes. 
Patients were considered to have undergone active treatment if 
they received chemotherapy (mainly platinum based) and/or radi-
cal radiotherapy. Continuous hyperfractionated accelerated radio-
therapy was not available at the time of recruitment of this cohort. 
Patients receiving palliative radiotherapy for symptom control 
and/or palliative care (symptom control without chemotherapy or 
radiation) were considered to have had palliative treatment.
Statistics
Grouping of the variables was carried out using stan-
dard thresholds for laboratory parameters. Data are presented 
as median and range. The relationships between the groups of 
patients were carried out using Mantel-Haenszel (χ2) test for 
trend and the Kruskal-Wallis test as appropriate. Univariate 
survival analysis and multivariate survival analysis with cal-
culation of hazard ratios (HRs) were performed using Cox’s 
proportional hazards model. A stepwise backward procedure 
was used to derive a final model of the variables that had a sig-
nificant independent relationship with survival. Deaths until 
october 2010 were included in the analysis. Analysis was per-
formed using SPSS software (SPSS, Inc., Chicago, IL).
RESULTS
Two hundred sixty-one patients with inoperable NSCLC 
were included in this study. The majority of patients were 
aged 65 years or older (68%), were men (59%), had BMI 
20 (89%), and an ECoG-PS 0 or 1 (54%). Most patients 
had a pretreatment CRP above the reference range (reference 
range: ø10 mg/L, 57%) and therefore a pretreatment mGPS 
= 1 (62%) and pretreatment PI = 1 (56%). only two patients 
with hypoalbuminaemia had normal CRP concentrations (i.e., 
GPS = 1 and mGPS = 0). The majority of patients had TNM 
stage III disease (51%) and received palliative treatment 
(63%). of all patients, 104 (40%) had their symptoms con-
trolled without chemotherapy or radiation. Sixty-one (23%) 
subsequently received palliative radiotherapy only, 59 (23%) 
received palliative chemotherapy only, 12 (5%) received radi-
cal radiotherapy, and 25 (10%) received chemoradiation. In 
patients with stage III disease (n = 134), 23 (17%) received 
chemotherapy only, 38 (28%) received radiation alone, and 
18 (13%) received chemoradiation. All patients with stage IV 
disease (n = 127) received platinum doublets (e.g., cisplatin 
plus vinorelbine or carboplatin plus gemcitabine) unless con-
traindicated, and 35 (28%) received palliative radiotherapy 
alone. The number of treatment cycles was not available for 
the analysis.
The median follow-up of the survivors was 83.1 months 
(range, 65.4–144.2 months). No patients were lost to fol-
low-up. The median survival of our patients from the date 
of diagnosis was 8.0 months (0.4–63.1 months). During the 
follow-up period, 248 (95%) patients died, 246 from their dis-
ease (noncancer causes of death included 1 patient who died 
of myocardial infarction and another congestive heart failure). 
The relationship between clinicopathological characteristics 
and cancer-specific survival is shown in Table 1. on univariate 
survival analysis, age (p < 0.001), ECoG-PS (p < 0.0001), 
mGPS (p < 0.0001), PI (p < 0.05), tumor stage (p ø t 0.001), 
and treatment received (p < 0.001) were significantly asso-
ciated with cancer-specific survival. on multivariate analysis 
of these significant variables, age (HR: 1.40, 95% confidence 
interval [CI]: 1.14–1.72, p = 0.001), ECoG-PS (HR: 1.26, 
95% CI: 1.05–1.50, p < 0.05), mGPS (HR: 1.67, 95% CI: 
1.28–2.19, p < 0.0001), and tumor stage (HR: 1.69, 95% CI: 
1.26–2.26, p < 0.0001) were independently associated with 
cancer-specific survival (Table 1). The cancer-specific survival 
curves for the mGPS, ECoG-PS, TNM stage, and treatment 
received are shown in Figures 1A–D.
Using 2-year cancer-specific mortality as an end point, 
the area under the receiver operator curve (RoC) was 0.618 
(95% CI, 0.532–0.704; p = 0.014) for the mGPS, 0.635 (95% 
CI, 0.548–0.722; p = 0.007) for ECoG-PS, and 0.574 (95% 
CI, 0.482–0.665; p = 0.122) for TNM stage. Using 5-year can-
cer-specific mortality as an end point, the area under the RoC 
was 0.735 (95% CI, 0.566–0.903; p = 0.024) for the mGPS, 
0.669 (95% CI, 0.489–0.848; p = 0.106) for ECoG-PS, and 
0.622 (95% CI, 0.437–0.807; p = 0.240) for TNM stage.
Baseline clinicopathological characteristics grouped 
according to the mGPS are shown in Table 2. Patients with an 
increased mGPS were more likely to have a poorer ECoG-PS 
(p < 0.05), an elevated white cell count (p < 0.05), and received 
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palliative treatment (p < 0.05). The relationships between the 
mGPS and cancer-specific survival in patients with better 
ECoG-PS (i.e., PS = 0 or 1) and poorer ECoG-PS (i.e., PS 
= 2 or 3) are shown in Figures 2A, B. The mGPS was associ-
ated with poorer cancer-specific survival in these groups of 
patients (HR: 1.49, 95% CI: 1.01–2.20, p = 0.042 and HR: 
1.70, 95% CI: 1.14–2.53, p = 0.009, respectively).
Because the mGPS was the most powerful prognostic 
factor, according to RoC analysis, the relationship between 
clinicopathological characteristics and cancer-specific survival 
in those patients with an mGPS of 0, 1, and 2 was examined 
in Table 3. In those patients with an mGPS of 0, 52 patients 
died of their cancer. on univariate survival analysis, BMI (p 
< 0.05) and ECoG-PS (p < 0.05) were significantly associ-
ated with cancer-specific survival. on multivariate analysis of 
these significant variables, only ECoG-PS (HR: 1.47, 95% CI: 
1.06–2.05, p < 0.05) was independently associated with can-
cer-specific survival. In those patients with an mGPS of 1, 158 
patients died of their cancer. on univariate survival analysis, 
age (p [ltequ] 0.001), ECoG-PS (p [ltequ] 0.01), TNM stage, (p 
[ltequ] 0.001), and treatment received (p < 0.01) were signifi-
cantly associated with cancer-specific survival. on multivariate 
analysis of these significant variables, only age (HR: 1.66, 95% 
CI: 1.27–2.16, p < 0.0001) and TNM stage (HR: 1.96, 95% 
CI: 1.37–2.82, p < 0.001) were independently associated with 
cancer-specific survival. In those patients with an mGPS of 2, 
38 patients died of their cancer. on univariate survival analysis, 
only treatment given (HR: 0.61, 95% CI: 0.45–0.84, p < 0.01) 
was significantly associated with cancer-specific survival.
The relationships between the mGPS and cancer-
 specific survival in patients who received palliative treat-
ments and active treatments are shown in Figures 3A, B. The 
mGPS was inversely associated with cancer-specific survival 
in patients who received palliative treatments (n = 165, HR: 
2.19, 95% CI: 1.63–2.93, p < 0.0001), with a similar trend 
in patients who received active treatments (n = 96, HR: 1.39, 
95% CI: 0.89– 2.17, p = 0.142).
CONCLUSION
The results of this study demonstrate the clinical util-
ity of the pretreatment mGPS, the most powerful prognos-
tic factor, because when the patients were stratified for the 
mGPS, no other factor whether it be ECoG-PS and clini-
cal TNM stage was consistently associated with cancer 
survival, independent of treatment received. For example, 
when those patients who had a good PS (ECoG-PS = 0 and 
1; Figure 2A) and most likely to receive active treatment 
in current treatment regimens were analyzed, it was clear 
that the mGPS further stratified those patients most likely 
to benefit from treatment. Also, when those patients with 
poorer PS (ECoG-PS  2; Figure 2B) and least likely to 
receive active treatment in current treatment regimens were 
analyzed, it was clear that the mGPS further stratified those 
patients least likely to benefit from treatment. In contrast, 
ECoG-PS did not consistently stratify patients within the 
mGPS groups confirming the superior prognostic value of 
the mGPS in patients with advanced NSCLC. Therefore, 
although mGPS and ECoG-PS are significantly associated, 
the mGPS has considerable clinical utility because it pro-
vides a superior objective pretreatment predictor of survival 
compared with the factors included in a routine clinical 
assessment, in particular, ECoG-PS. Given the rapid pro-
gression of the disease and short survival of patients with 
inoperable NSCLC, these results would suggest that the 
simple, objective, and well-standardized mGPS should form 
a regular part of a clinical pretreatment assessment.
The results of this study are consistent with the work 
of Crumley et al.20 who have proposed a new clinical staging 
TABLE 1. Clinicopathological Characteristics in Patients with Inoperable Non-small Cell Lung Cancer (n=261). Univariate and 
Multivariate Survival Analysis for Cancer Specific Survival.
 Univariate Survival Analysis Multivariate Survival Analysis
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Patient related
 Age (,65/65274/.75yr) 1.39 (1.1721.66) ,0.001 1.40 (1.1421.72) 0.001
 Gender (male/female) 1.09 (0.8521.41) 0.500
 BMIa (,20/<20) 0.86 (0.5821.28) 0.455
 ECoG-PSb (0/1/2/3) 1.46 (1.2421.72) ,0.001 1.26 (1.0521.50) 0.011
 White cell count (109/L) (#11/11) 1.23 (0.9321.61) 0.143
 mGPS (0/1/2) 1.83 (1.4422.34) ,0.0001 1.67 (1.2822.19) ,0.0001
 PI (0/1/2) 1.28 (1.0621.54) 0.011
Tumor related
 Pathology (Squamous/adenocarcinoma/
other/no pathology)
0.96 (0.8321.12) 0.610
 Tumor stage (III/IV) 1.56 (1.2122.01) 0.001 1.69 (1.2622.26) ,0.0001
 Treatment (palliative/active) 0.60 (0.4620.78) ,0.0001
a BMI, n 5 190.
b ECoG-PS, n 5 206.
mGPS, modified prognostic score; CI, confidence interval; BMI, body mass index; ECoG-PS, Eastern Cooperative oncology Group performance status; PI, prognostic index.
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system based on mGPS in patients presenting with gastroe-
sophageal cancer, also an aggressive cancer. It is of interest 
that Iimura et al.21 recently reported the development and vali-
dation of the TNM-CRP score in patients undergoing nephre-
ctomy for renal clear cell cancer. A similar approach has also 
been carried out in bladder cancer.22 Recently, in almost 9000 
patients, the mGPS was shown to be superior to other markers 
of the systemic inflammatory response across a wide variety 
of cancers.23 Therefore, we believe that the mGPS should be 
incorporated into the routine clinical pretreatment assessment 
of patients with cancer.
As demonstrated in this study, the pretreatment mGPS 
identifies a subgroup of patients with advanced NSCLC who 
are at higher risk of dying from their disease, independent of 
FIGURE 1. A, The relationship between the modified Glasgow prognostic score (mGPS; 0, 1, 2 from top to bottom) and 
cancer-specific survival in patients with inoperable non-small cell lung cancer (p < 0.0001). B, The relationship between tumor, 
node, metastasis (TNM) stage (III, IV from top to bottom) and cancer-specific survival in patients with inoperable non-small cell 
lung cancer (p = 0.001). C, The relationship between Eastern Cooperative Oncology Group performance status (ECOG-PS)  
(PS = 0 to 3 from top to bottom) and cancer-specific survival in patients with inoperable non-small cell lung cancer (p < 0.001). 
D, The relationship between treatment received (palliation only to chemoradiation from top to bottom) and cancer-specific 
survival in patients with inoperable non-small cell lung cancer (p < 0.0001).
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tumor stage and regardless of treatment they subsequently 
received. It is reasonable to propose that the mGPS is used 
routinely to inform the planning of supportive measures for 
these patients, and patients with a systemic inflammatory 
response may benefit from closer follow-up or earlier involve-
ment of palliative care.
The basis of the relationship between the systemic 
inflammatory response (mGPS) and poorer cancer-specific 
survival is unclear and likely to be multifactorial. However, 
it is clear that systemic inflammatory markers, such as 
CRP, play an important role in the tumor-host relationship. 
Increased CRP level is associated with lymphocytopenia and 
impaired T lymphocytic response within the tumor,24,25 as 
well as the upregulation of components of the innate immune 
system, including complement and macrophage function.24,26 
Moreover, proinflammatory cytokines and growth factors, 
which may promote and maintain tumor growth, are also 
increased as part of the systemic inflammatory response.27,28 
The mGPS resulted from the realization that the process of 
cachexia in patients with cancer resulted mainly from an 
ongoing systemic inflammatory response. The rationale and 
development of the mGPS, from the selective combination of 
CRP and albumin, have been previously described in detail.18
A strength of this study is that it examines the clini-
cal utility of the mGPS in a mature cohort of patients with 
advanced NSCLC, i.e., 95% of patients had died on follow-up. 
TABLE 2. Clinicopathological Characteristics and Treatment Received in Patients in Patients with Inoperable Non-small Cell 
Lung Cancer (n= 261).
mGPS 5 0
n 5 59 (%)
mGPS 5 1
n 5 163 (%)
mGPS 5 2
n 5 39 (%) P
Patient related
 Age
  ,65 22 (37) 49 (30) 13 (33) 0.571
  65274 22 (37) 76 (47) 11 (28)
  75 15 (25) 38 (23) 15 (38)
 Gender
  Female 28 (47) 102 (63) 24 (62) 0.122
  Male 31 (53) 61 (37) 15 (38)
 BMIa
    ,20 10 (19) 16 (13) 4 (14) 0.459
  20 42 (81) 104 (87) 14 (86)
 ECoG-PSb
  0 13 (25) 19 (15) 2 (8) 0.015
  1 18 (35) 53 (41) 7 (29)
  2 13 (25) 46 (35) 4 (17)
  3 8 (15) 12 (9) 11 (46)
 White cell count (109/L)
  11 48 (81) 114 (70) 22 (56) 0.029
    .11 11 (19) 49 (30) 17 (44)
 PI
  0 48 (81) 0 (0) 0 (0) <0.0001
  1 11 (19) 114 (70) 22 (56)
  2 0 (0) 49 (30) 17 (44)
Tumor related
 Pathology
  Squamous 17 (29) 66 (40) 12 (31) 0.968
  Adenocarcinoma 16 (27) 35 (21) 8 (21)
  other 4 (7) 10 (6) 5 (13)
  No pathology 22 (37) 52 (32) 14 (44)
 TNM Stage
  III 27 (46) 92 (56) 15 (38) 0.082
  IV 32 (54) 71 (44) 24 (62)
 Treatment
  Palliative 40 (68) 93 (57) 32 (82) 0.011
  Active 19 (32) 70 (43) 7 (18)
a BMI, n 5 190.
b ECoG-PS, n 5 206.
mGPS, modified prognostic score; BMI, body mass index; ECoG-PS, Eastern Cooperative oncology Group performance status; PI, prognostic index; TNM, tumor, node, 
metastasis.
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However, given that the patients studied were recruited 
between 2001 and 2004, a limitation of this study is that treat-
ment regimes have changed over this period, and it is not clear 
whether these results can be extrapolated to current treatment 
regimes. Nevertheless, it is important to note the consistency 
FIGURE 2. A, The relationships between modified Glasgow 
prognostic score (mGPS) and cancer-specific survival in 
patients with inoperable non-small cell lung cancer and 
Eastern Cooperative Oncology Group performance status 
(ECOG-PS) = 0 or 1 (p = 0.042). B, The relationships between 
mGPS and cancer-specific survival in patients with inoperable 
non-small cell lung cancer and ECOG-PS = 2 or 3 (p = 0.009).
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and reliability of the prognostic value of the mGPS across 
tumor types and treatment regimes,6,23,29,30 which make it 
likely that the mGPS will also have clinical utility in the most 
recent treatment regimens. Prospective studies, ideally within 
the context of randomized controlled trials, will be required 
to confirm whether targeting patients with advanced NSCLC 
and a systemic inflammatory response with active oncological 
treatment confers significant clinical benefit.
In summary, in this study, we have shown the clinical 
utility of the pretreatment mGPS as the basis of predicting 
likely cancer-specific survival in patients with inoperable 
NSCLC. The mGPS is an objective measurement readily 
applied in a standard clinical setting, and consideration should 
be given to its routine clinical use.
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